Xcout Intel
Optimvia, LLC
Optimvia is a biopharmaceutical company that utilizes its proprietary ADEPT discovery platform to engineer enzymes for synthesizing complex therapeutic molecules. The company's primary product is a commercially viable, biosynthetic alternative to animal-derived heparin, aimed at replacing traditional livestock-sourced supplies and developing novel heparin-based pharmaceuticals.
Subscribe to see Optimvia, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Optimvia, LLC at a glance
Optimvia, LLC is a biotechnology company headquartered in United States. It has raised at least $12.5M across the 4 funding rounds on record. Its most recent funding round raised $75,000 in March 2026. Xcout tracks 10 named people at Optimvia, LLC, including Keith M. Kleeman (Manager and Chief Executive Officer).
Optimvia, LLC leadership
- Keith M. KleemanManager and Chief Executive Officer
- Edmundo MunizDirector
- James E RothmanDirector
- James RothmanDirector
- John BaldoniDirector
- Keith KleemanDirector
4 more named people on record for Optimvia, LLC, with roles, board committees and tenure — see the full roster →
Optimvia, LLC funding rounds
At least $12.5M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $75,000 | — | |
| SEC Form D filing | $5M | — | |
| SEC Form D filing | $5M | — | |
| SEC Form D filing | $2.4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Optimvia, LLC competitors
A few of Optimvia, LLC's closest competitors — see the full list of competitors and alternatives →
CHARM Therapeutics Inc. is a biopharmaceutical company utilizing proprietary technology platforms for drug discovery and therapeutic pipeline development.
Operating within the United States, eXoZymes, Inc. is a pioneering synthetic biochemical enterprise. The company's primary innovation is SimplePath, a sophisticated platform engineered to synthesize a diverse spectrum of chemicals. This output encompasses essential pharmaceuticals, alternative fuels, advanced materials, food additives, and entirely new molecular entities. Integral to its design, the SimplePath platform incorporates distinct modules, each housing one or more enzymes that work synergistically to facilitate specific biocatalytic transformations. The firm was established in 2014 and maintains its corporate headquarters in Monrovia, California.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Scala Biodesign develops computational protein design technologies to optimize enzymes, antibodies, therapeutic proteins, and antigens for industries such as pharmaceuticals and chemicals.
Antheia, Inc. is an advanced biotechnology research and biosynthesis company headquartered in Menlo Park, California, delivering 21st-century pharmaceutical solutions.
Alteogen is a biotechnology company that researches and develops next-generation bio-betters, biosimilars, and proprietary drug delivery platforms, including long-acting technologies, antibody-drug conjugates (ADCs), and subcutaneous injection conversion technologies. The company serves the global pharmaceutical and healthcare industries by developing advanced biologic drugs and platform solutions.
Get Optimvia, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Optimvia, LLC in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access